Company History

 
September,
2021
The former Saitama factory of Kayaku Company Limited newly started operation as Sun Pharma Japan Technical Operations Limited.
Continues to manufacture Lulicon® and other Sun Pharma topical products.
April,
2021
Succeeded manufacturing and marketing authorization for Gemcitabine from Taiho Pharmaceutical Company Limited and began sales in June 2021
December,
2020
Succeeded manufacturing and marketing authorization for Irinotecan from Taiho Pharmaceutical Company Limited and began sales
September,
2020
Launched Ilumya® (tildrakizumab) for the treatment of plaque psoriasis, which is the first new biologics for Sun Pharma Japan in the Japanese market.
January,
2020
Merged with Pola Pharma Inc.
September,
2016
Announced the succession for manufacturing and marketing authorization for 14 long listed brands from Novartis Pharma K.K.
March,
2012
Sun Pharma Japan Limited was established in Japan